Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Colorcon
Dow
McKesson
Boehringer Ingelheim

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Patent: 9,931,330

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,931,330
Title:Methods and devices for the treatment of ocular diseases in human subjects
Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
Inventor(s): Zarnitsyn; Vladimir (Atlanta, GA), Patel; Samirkumar (Atlanta, GA), White; Daniel (Suwanee, GA), Noronha; Glenn (Atlanta, GA), Burke; Brian (Cary, NC)
Assignee: CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA)
Application Number:15/673,073
Patent Claims:see list of patent claims

Details for Patent 9,931,330

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2032-11-08
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 1998-05-12 ⤷  Free Forever Trial 2032-11-08
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 2003-01-02 ⤷  Free Forever Trial 2032-11-08
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Free Forever Trial 2032-11-08
Immunex Corporation ENBREL etanercept For Injection 103795 1998-11-02 ⤷  Free Forever Trial 2032-11-08
Immunex Corporation ENBREL etanercept For Injection 103795 1999-05-27 ⤷  Free Forever Trial 2032-11-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Harvard Business School
McKinsey
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.